Adverse events after transcatheter edge-to-edge repair: descriptive post-marketing surveillance analysis of MitraClip and PASCALTM from the Manufacturer and User Facility Device Experience (MAUDE) registry Authors: Ananya Kommuri, Adwoa Boatemaah Adu-Sarkodee, Sheriff N. Dodoo Published: 2026 ABSTRACT BackgroundTranscatheter edge-to-edge repair (TEER) has emerged as a pivotal intervention for patients with severe mitral regurgitation (MR). The MitraClip and PASCALTM devices are two leading percutaneous devices developed for TEER. While both devices are effective, comparative real-world adverse event data between the two remain limited. This study aims to analyze the post-marketing device-related adverse event profiles associated with the MitraClip and PASCAL device using the Food and Drug Administration (FDA)’s Manufacturer and User Facility Device Experience (MAUDE) database.MethodsWe queried the MAUDE database from September 2022 to August 2025 for device-related adverse events reported for the MitraClip and PASCAL systems in the United States. After excluding duplicate reports, 518 reports were included in this study. Adverse events were categorized into 13 clinical outcomes, with comparative analyses being performed for each category.ResultsOf the adverse events reported, device detachment or malfunction was the most frequently reported device-related event and was more common with the MitraClip than the PASCAL system [47.98% vs. 20.83%, 95% confidence interval (CI): 1.408–13.855; P=0.005]. Valve apparatus tear reports between the two devices were similar (24.49% vs. 16.66%, 95% CI: 0.529–6.648; P=0.47). Device embolization was also similar when the MitraClip group was compared to those who received the PASCALTM device (7.90% vs. 4.17%, 95% CI: 0.303–83.250; P>0.99). Mortality and other major complications, such as cardiogenic shock and pericardial effusion, were rare and statistically similar between both groups.ConclusionsThis MAUDE-based post-marketing analysis identifies device detachment/malfunction during device deployment as the most frequently reported event category among submitted reports, particularly in the MitraClip cohorts and among patients receiving the PASCALTM for severe MR. However, due to passive reporting, lack of denominator data, and marked cohort imbalance, these findings are descriptive and hypothesis-degenerating rather than definitive comparative safety outcomes. Highlight box Key findings • This Manufacturer and User Facility Device Experience (MAUDE) post-marketing surveillance analysis of 518 transcatheter edge-to-edge repair (TEER) adverse-event reports found device detachment/malfunction to be the most frequently reported event, more often reported with MitraClip than PASCAL. Valve apparatus tear, embolization, cardiogenic shock, mitral stenosis, pericardial effusion, and death were the other device-related adverse event categories. What is known and what is new? • TEER with MitraClip and PASCAL is an established option for selected high-risk patients with severe mitral regurgitation, and prior trials suggest favorable safety and efficacy. • This manuscript adds real-world post-Food and Drug Administration-approval surveillance data outlining reported adverse-event patterns for MitraClip and PASCAL in the MAUDE database. It highlights device detachment/malfunction—especially incomplete coaptation, single-leaflet device attachment, and device dislodgement—as the dominant reported procedural issue. What is the implication, and what should change now? • These findings should be interpreted as descriptive safety signals, not comparative incidence rates, because MAUDE lacks denominator data, adjudication, and balanced device exposure. Clinicians should remain vigilant for deployment-related complications and consistently report events. Definitive comparisons require prospective registries with denominator capture, standardized adjudication, mitral regurgitation etiology stratification, device-generation data, and case-mix adjustment. Introduction Mitral regurgitation (MR) is one of the most common valvular heart diseases, leading to increased mortality, morbidity, and impacting quality of life (1). MR affects approximately 2–3% of the global population, mainly elderly individuals (1), with an annual death rate of more than 5% (2). Furthermore, those with heart failure with reduced ejection fraction, the presence of severe MR if left untreated, can cause a one-year mortality up to 57% (3). Mitral valve surgery, including repair or replacement, is considered the standard of care for patients with severe symptomatic MR who require intervention (4-6). However, for those who are at high prohibitive risk for surgical intervention, the therapeutic options are limited (7-9). Inspired by the Alfieri Stitch (10), a percutaneous catheter-based implantable clip system, MitraClip, was developed to address this significant unmet clinical need. Following initial preclinical work from the Endovascular Valve Edge-to-Edge Repair Study (EVEREST) Phase 1 trial (11), feasibility and safety data from the EVEREST II study (12), the MitraClip was tested in the seminal Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) trial, which demonstrated that transcatheter mitral valve repair using the MitraClip resulted in significant additional clinical benefit in patients with symptomatic heart failure and moderate-to-severe or severe secondary MR who are already on maximal tolerated guideline-directed medical therapy (GDMT) (13). The practice guideline now recommends that transcatheter edge-to-edge repair (TEER) using the MitraClip device can be considered in patients with severe primary MR and symptoms, or with left ventricular dysfunction, who are at high or prohibitive risk for surgical intervention (14). Furthermore, in those with secondary severe MR and persistent symptoms, with left ventricular dysfunction on maximally tolerated GDMT and favorable mitral valve anatomy, TEER can be considered following collaborative heart valve team evaluation (14). Following the adoption of MitraClip, another catheter-based technology, the PASCALTM transcatheter valve system, designed by Edwards Lifesciences, was introduced, further expanding percutaneous options for patients with severe MR. The PASCALTM transcatheter valve system was successfully tested in patients with primary MR [degenerative mitral regurgitation (DMR)] who were considered at prohibitive risk for mitral valve surgery (15,16). The PASCALTM device is larger than the MitraClip, featuring a center spacer and broad paddles to secure the mitral valve leaflets at the center spacer. Additionally, the PASCALTM device primarily uses nitinol, whereas MitraClip devices are made of cobalt-chromium. The positive results from the Edwards PASCAL TranScatheter Valve RePair System Pivotal Clinical (CLASP II D) study (16), which showed the safety and effectiveness of PASCALTM devices compared to MitraClip in patients with significant symptomatic primary MR who are at prohibitive risk for surgical intervention, led to the PASCALTM transcatheter valve system receiving approval by the US Food and Drug Administration (FDA) in 2022. To date, multiple small studies have demonstrated the overall efficacy and comparable periprocedural outcomes between these two devices (17-20). Recently, Hosseini and his colleagues reported results of their head-to-head comparison of PASCAL and MitraClip outcomes, which showed that both devices had similar 30-day all-cause mortality, MR reduction to 2+ MR, and New York Heart Association (NYHA) improvement. They stated that periprocedural events, including periprocedural death and stroke, were few and similar between the two cohorts (17). The periprocedural events studied in their meta-analysis did not include device-specific adverse events, such as those studied in our post-marketing surveillance analysis, including device detachments, inability to release device during deployment, single leaflet attachment etc. Additionally, prior studies have had small sample sizes and are underpowered to detect rare device-related adverse events (18,19). Furthermore, there is a dearth of comparative real-world post-marketing surveillance data for these two mitral valve systems following their FDA approval. In this context, we performed a post-FDA-approval descriptive surveillance of adverse events in patients with MR following TEER with the MitraClip and the PASCALTM device using the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database. Prior randomized and observational studies, including CLASP IID (16), Transcatheter Repair of Mitral Regurgitation with Edwards PASCAL Transcatheter Valve Repair System (MiCLASP) (20), recent propensity-matched multicenter analysis (18), and meta-analysis (17), have demonstrated broadly similar procedural outcomes between devices, although power for rare adverse events remains limited. We present this article in accordance with the STROBE reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0781/rc). Methods The MAUDE database is a publicly accessible electronic registry of adverse events related to medical devices reported voluntarily following FDA approval (21). Adverse events in the MAUDE database are reported voluntarily by medical device manufacturers, distributors, healthcare professionals, and patients (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm). Two authors (A.K. and S.N.D.) independently queried the MAUDE database between September 2022 and August 2025 for all device-related adverse events associated with the MitraClip and PASCALTM devices following FDA approval. These device-related adverse events were individually vetted by the third author (A.B.A.S.); final validation and extensive review of these reports were conducted by the authors (A.K., A.B.A.S., S.N.D.). A safety profile analysis of adverse events related to the PASCAL device was conducted in a descriptive fashion, juxtaposed with those related to MitraClip use over the same period. The following filters were used for the search: product code “NKM” (FDA-assigned code for Mitral Valve Repair Devices), product class “Mitral Valve Repair Devices”, brand name “PASCAL Precision system”, and brand name “MitraClip”. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study did not require IRB approval and was deemed IRB-exempt because the MAUDE database is publicly available and contains de-identified patient data. Following the query, a total of 715 adverse event reports were identified, and during screening, 23 duplicate reports were excluded. Following critical adjudication of reports, 17 review reports, 66 reports before FDA approval of the devices, and 91 reports with incomplete or insufficient data were excluded. A total of 518 independent reports were included in the final analysis, of which 494 were MitraClip-related and 24 PASCAL-related adverse reports (Figure 1). Schematic flow diagram of search strategy of the MAUDE database conducted for MitraClip and PASCAL related adverse reports from September 2022 to August 2025. FDA, Food and Drug Administration; MAUDE, Manufacturer and User Facility Device Experience. The device-related adverse events were categorized into 13 entities: cardiogenic shock, mitral stenosis, pericardial effusion, cerebrovascular accident (CVA)/transient ischemic attacks (TIAs), vascular injury, device embolization, venous thromboembolism (VTE), valve apparatus tear, nonspecific ST/T wave changes, device detachment/malfunction, myocardial wall/atrial perforation, air embolism, and death. The 13 endpoints were unadjusted numerical counts of device-related adverse events. An analysis was performed to determine the most common cause of malfunction during device deployment between the MitraClip and the PASCAL systems. Statistical analysis To ensure the consistency and accuracy of the collected data, two investigators (S.N.D. and A.B.A.S.) independently analyzed it. Categorical variables were expressed as percentages of the total number of device-related adverse event reports as captured in the MAUDE database. Fisher’s exact test was used to compare categorical variables between the two groups; however, given the highly imbalanced group sizes and the lack of denominator data in the MAUDE database, this analysis should be considered exploratory rather than inferential. A P value <0.05 was considered statistically significant. All statistical analyses were performed using STATA software version 18.0 (StataCorp-LLC, College Station, TX, USA). Statistical analyses were exploratory and hypothesis-generating only. Results A total of 518 device-related adverse event reports were recorded in the MAUDE database during the study period for both MitraClip and PASCALTM devices, based on the eligibility criteria used for this analysis (MitraClip-related adverse event reports, n=494; PASCALTM-related adverse event reports, n=24). Figure 1 presents a schematic flow diagram of the search strategy used in the MAUDE database to identify MitraClip- and PASCAL-related adverse events over the study period. The most frequently reported device-related adverse events were device detachment or malfunction during deployment (MitraClip 47.98% (n=253) vs. PASCAL 20.83% (n=5), 95% CI: 1.408–13.855, P=0.005) (Figure 2). Device-related adverse event following TEER using MitraClip versus PASCAL device from September 2022 to August 2025. CVA, cerebrovascular accident; TEER, transcatheter edge-to-edge repair; TIA, transient ischemic attack. The second most reported device-related adverse event was device-related valve apparatus rupture or tear [MitraClip 24.49% (n=121) vs. PASCAL 16.66% (n=4), 95% CI: 0.529–6.648; P=0.47) (Figure 2). Intraprocedural device embolization was similar when the MitraClip cohort was compared with patients who received PASCALTM over the study period [MitraClip 7.90% (n=39) vs. PASCAL 4.17% (n=1), 95% CI: 0.303–83.250, P>0.99] (Figure 2). Device-related cardiac tamponade or pericardial effusion adverse events were relatively low and similar between both cohorts [MitraClip 1.43% (n=7) vs. PASCAL 4.17% (n=1), P=0.35] (Figure 2). There was no difference in device related mitral stenosis [MitraClip 3.03% (n=15) vs. PASCAL 4.17% (n=1), P=0.34], cardiogenic shock [MitraClip 4.04% (n=20) vs. PASCAL 4.17% (n=1), P=0.67) and death [MitraClip 4.04% (n=20) vs. PASCAL 4.17% (n=1), P=0.21] (Figure 2). The three most common causes of device detachment or malfunction during deployment were incomplete coaptation (MitraClip, n=69 vs. PASCAL, n=1), followed by single leaflet device attachment (MitraClip, n=44 vs. PASCAL, n=2) and dislodgement of device (MitraClip, n=42 vs. PASCAL, n=1) (Figure 3). The most common causes of malfunctioning of device deployment of MitraClip (n=253) versus PASCAL precision system (n=5) from September 2022 to August 2025. Discussion Importantly, the current analysis should be interpreted strictly as a descriptive characterization of reported post-marketing adverse-event patterns in MAUDE, rather than as a definitive comparative safety study. MAUDE lacks denominator implantation data, standardized adjudication, and detailed patient-level information; therefore, proportions of reported events cannot be interpreted as procedural incidence rates or relative risks. The marked imbalance between MitraClip and PASCALTM reports (494 vs. 24) substantially limits statistical inference. Several event categories contained only 0 to 1 PASCALTM reports, resulting in wide CIs and low statistical power. Accordingly, all P values should be interpreted as exploratory and hypothesis-generating rather than confirmatory. Differences in approved indications and MR etiology likely contributed to reporting heterogeneity. MitraClip has broader adoption across both primary and secondary MR populations, whereas PASCALTM initially received approval for prohibitive-risk primary MR. These populations differ substantially in annular geometry, ventricular remodeling, leaflet pathology, and procedural complexity, introducing confounding by indication. The key findings of this analysis are (I) the safety profile of both mitral valve devices, whether MitraClip or PASCALTM, remained favorable following FDA approval during the study period. This is evidenced by the relatively low death-related events and complications, including cardiogenic shock, mitral stenosis, and cardiac tamponade/ effusion; (II) the most common non-death-related procedural adverse event was device detachment/malfunction during deployment; (III)of the reported causes of device failure during deployment, device detachment or malfunction, incomplete coaptation, single-leaflet device attachment, and complete device dislodgement were the most common. The safety profile of both devices, whether MitraClip or PASCALTM, has been established in several randomized controlled trials, including COAPT and CLASP (13,15). However, the devices’ safety was tested in the trial environment under strict research protocols and frequent clinical follow-up. It was important to assess their safety in a real-world environment after the US FDA approved them. Interestingly, the safety profile of these devices, whether MitraClip or PASCALTM, in this analysis was consistent with the seminal COAPT (13) and CLASP II D trials (16), as well as other observational studies (22,23) reporting direct comparisons of these devices. To the best of our knowledge, no previous studies have thoroughly analyzed the post marketing safety surveillance of these devices in the real-world setting following FDA approval. Device detachment or malfunction during deployment was the most frequently reported adverse event and was more common in MitraClip patients. Multiple reasons for device detachment or malfunction include incomplete coaptation, difficulty removing or positioning, difficulty opening the grippers, inability to release the device from a single-leaflet attachment, and device dislodgement (Figure 3). Since its inception, MitraClip has undergone multiple iterations, with the latest being G5, which includes improvements such as independent leaflet grasping and a redesigned arm to reduce leaflet stress. Currently, the G5 MitraClip is available in four different sizes (NT, NTW, XT, XTW), and the PASCAL device is available in two different sizes (PASCAL P10 and PASCAL Ace). The original PASCAL P10 features a central spacer with a paddle 10 mm in width, while the more recent iteration, PASCAL Ace, has a less prominent spacer, akin to the design profile of MitraClip. Furthermore, while the MitraClip device is indicated for both high-risk primary severe MR and secondary MR, the PASCALTM device is currently FDA approved for high-risk severe primary MR. The broader FDA-approved indication of the MitraClip device may account for its greater use in MR patients considered high risk for surgical intervention, compared with the PASCAL device. These assertions may translate into the higher adverse event signal observed in our study, although definitive attribution of the higher MAUDE reports for the MitraClip cannot be confirmed by our study. Furthermore, given that interventional operators appear to have a wide range of sizes with the MitraClip, they are more likely to use the MitraClip rather than the PASCAL device; thus, more MitraClip-related adverse events are captured in the MAUDE database, as seen in our analysis. The inherent limitation of this current study precludes a conclusive comparison of the two devices. Additionally, we do not know the type of MitraClip or the total number of implantations of either MitraClip or PASCAL during the study period; hence, we are unable to make inferences relating to the impact of the type of MitraClip or PASCALTM device implanted on the incidence of the adverse events captured in the MAUDE database. However, in this study population, there is greater evidence of single-leaflet device attachment with MitraClip than in the previous multicenter study by Mauri et al., which demonstrated that, despite predominantly using first- or second-generation MitraClip NT, there was no difference in single-leaflet device attachment between the two devices (18). Several reasons could account for the relatively higher reported device detachment or malfunction in the MitraClip group compared with the PASCAL group, including increasingly difficult mitral valve anatomy in those with severe MR undergoing TEER (24). Additionally, while the MitraClip device is indicated for both high-risk primary severe MR and secondary MR, the PASCALTM device is currently FDA approved for high-risk severe primary MR. The broader FDA-approved indication of the MitraClip device may account for its greater use in MR patients considered high risk for surgical intervention, compared with the PASCAL device. These assertions may translate into the higher adverse event signal observed in our study, although definitive attribution of the higher MAUDE reports for the MitraClip cannot be confirmed by our study. Furthermore, given that interventional operators appear to have a wide range of sizes with the MitraClip, they are more likely to use the MitraClip rather than the PASCAL device; thus, more MitraClip-related adverse events are captured in the MAUDE database, as seen in our analysis. The inherent limitation of this current study precludes a conclusive comparison of the two devices. In this post-FDA approval analysis, valve apparatus tear or rupture is the second-most-reported adverse event with similarly reported in both MitraClip and PASCALTM groups. Additionally, it is important to note that procedure-related adverse events related to the valve apparatus for MitraClip procedures are generally similar to those reported for the PASCALTM device. This may be attributed to the similarity in the procedural steps in device deployment. Limitations The findings of this analysis using the MAUDE database should be interpreted within several limitations, including the absence of MR etiology classification, echocardiographic anatomy, device-generation stratification (e.g., MitraClip G4/G5 versus PASCAL Ace), operator experience, and procedural-volume data. Reporting bias may also differ between an established device and a newly approved platform under heightened surveillance. Several alternative explanations for the asymmetric reporting deserve discussion, in particular, reporting bias related to longer market presence, high case volumes, and operator experience with M-TEER (especially in Germany and other early-adopter regions), as well as differences in post-marketing surveillance intensity between the two manufacturers. Additionally, the MAUDE registry relies on mandatory reporting by manufacturers, importers, and device user facilities, but on voluntary reporting by health care professionals, patients, and consumers; some safety events may therefore be underreported, including mechanisms of device failure. Furthermore, some events are overreported when both mandatory and voluntary reporters report the same event. Furthermore, there is no independent organization that verifies the accuracy of these events, as the FDA only gathers information about adverse events without thorough adjudication. Additionally, because it does not provide total device utilization for either MitraClip or PASCAL during this time frame, we could not calculate the incidence and prevalence of these device-related complications. Hence, an accurate comparison across the devices is not feasible. Finally, the MAUDE database does not capture patient demographics, comorbidities, baseline valve anatomy, including MR etiology (primary vs. secondary), ejection fraction, prior procedures, operator volume, and other patient-level data. These factors significantly influence procedural outcomes in TEER, including the choice of the device types, whether MitraClip or PASCAL, used in the TEER procedure. Without any of this information, it is not possible to draw clinically meaningful conclusions about the device-specific safety signal seen in our study. Conclusions This MAUDE-based post-marketing surveillance analysis describes the spectrum of reported adverse events associated with MitraClip and PASCALTM devices following FDA approval. Because MAUDE lacks denominator data on implantation and contains passive, voluntary reports with highly imbalanced cohorts, these findings should not be interpreted as true comparative incidence rates or definitive head-to-head safety comparisons. Device detachment/malfunction represented the most frequently reported event category among submitted reports, particularly in the MitraClip cohort; however, this observation may reflect differences in market penetration, procedural volume, MR etiology, reporting behavior, and case complexity rather than intrinsic device-related risk. Prospective registries with denominator capture, adjudicated outcomes, MR etiology stratification, and case-mix adjustment are required for definitive comparative safety assessment. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0781/prf